Long-Term Extension Data Demonstrates Sustained Effect of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Long-Term Extension Data Demonstrates Sustained Effect of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

New data reveals vidofludimus calcium effectively maintains low disability progression in relapsing-remitting multiple sclerosis over 144 weeks, enhancing patient quality of life.

Spotlight on More-EUROPA: Bridging Real-World Data and Clinical Evidence for Better MS Care

At the EMSP Annual General Meeting 2025, we were delighted to present the More-EUROPA project—a collaborative effort funded by the European Union’s Horizon Europe programme (Grant No. 101095479). This five-year project, which began in January 2023, brings together 14 public and private organisations from seven EU countries. The goal of More-EUROPA is to use real-life health data (called real-world data or RWD) to help experts make better decisio…

Vidofludimus calcium shows benefits for most RRMS patients: Trial

More than 90% of relapsing-remitting multiple sclerosis (RRMS) patients who received Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium have not experienced confirmed disability worsening after nearly three years. That’s according […] The post Trial: Vidofludimus calcium shows benefits for 9 of 10 RRMS patients appeared first on Multiple Sclerosis News Today.

Immunic reports positive long-term OLE data from trial of IMU-838 in RRMS - BioTuesdays

Immunic (NASDAQ: IMUX) has announced new, positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) in patients with relapsing-remitting multiple sclerosis (RRMS). The data at week 144 showed that 92.3% of patients remained free of 12-week confirmed disability worsening (CDW) events, as measured by the Expanded Di…